Step 15 — Scenario, Stress, and Base-Rate Analysis

Date: 2026-04-27 Sector Track: Insurer

1. Key Findings

• Probability-weighted fair value: $68/share (-3.4% downside from spot $65.71). Scenarios: Bull 25% × $100 + Base 45% × $72 + Bear 25% × $40 + Severe 5% × $20 = $25 + $32.4 + $10 + $1 = $68.4.
• Bull case ($100, 25% probability): LR 58-60% terminal, FY28 EBITDA +$300M, FY30 +$600M. Requires (a) AI cost-structure compression to 10% LAE benchmark holds, (b) Lemonade Autonomous Car captures 20%+ of Tesla US fleet, (c) Europe IFP scales to $400M by FY28, (d) no material CAT event.
• Base case ($72, 45% probability): Per Step 14 — LR 62-64%, FY28 EBITDA +$200M, FY30 +$400M. Requires execution per management commitments and routine CAT load.
• Bear case ($40, 25% probability): LR reverts to 70-72% under cycle softening + AI commoditization; FY28 EBITDA -$100M; growth-spend ramp doesn't translate to LTV expansion. Stock trades at 5-6x P/B + reduced premium.
• Severe case ($20, 5% probability): Major CAT event ($150M+ EBITDA hit), reinsurance counterparty crisis, AI commoditization full impact, GLR back to 80%+. P/B compresses to 3x (full neoinsurer post-failure repricing).
• Base rate analysis: LMND's required FY26 IFP +32% growth is historically achievable (FY24 was +26%; FY25 +31%; sustained 25-32% has been delivered for 3 years). FY27-30 IFP growth +25% → +12% terminal is conservative vs sub-market growth in pet (+17.5%) and EU. Loss-ratio improvement to 62% is ambitious but in line with management's 12-quarter trajectory.
• Kahneman bias check: Anchoring on the FY27 first-full-year-EBITDA-positive guide is the cleanest planning-fallacy risk. Saliency bias on March 2026 co-founder buying could overweight insider-conviction signal. Watch for survivorship bias in peer comparison (we exclude failed insurtechs like Bright Health from cohort medians).
• Net thesis impact: Net mixed — slightly negative skew at current price. PWFV $68 vs spot $65.71 = -3.4% downside (within noise). Risk/reward is fair at current price; compelling at $50-55; unattractive above $85.

2. Implications for Thesis and Valuation

• Recommendation: HOLD existing position; ACCUMULATE only at $50-58 entry zone (provides 25-40% margin of safety to base $72)
• Position sizing: Quarter-Kelly approach — at $65.71, edge = ($68 - $65.71) / $65.71 = 3.5%; with high uncertainty (high beta 2.04, 14.27% short interest, narrow moat), 1/4 Kelly = ~3-5% portfolio weight max
• Time horizon: 3-5 years to capture FY27 GAAP-positive inflection through FY30 terminal compounding
• Stop-loss (informally): Stock <$45 implies bear case is materializing (LR reversal, cycle hit) — re-evaluate thesis
• Take-profit (informally): Stock >$110 implies bull case is fully priced — trim toward 1/4 Kelly

3. Objective

Build bull, base, bear, severe scenarios; stress key variables; use peer and historical base rates; apply Kahneman bias checklist; document where biases may distort base case.

4. Narrative Analysis

Scenario Definitions

Bull Case ($100/share, 25% probability)

Operating assumptions:

• IFP CAGR FY25→FY30: +25% (vs base +20%)
• Loss ratio FY28-30: 58-60% (vs base 62-64%)
• Lemonade Autonomous Car: captures 20%+ of Tesla US fleet by FY28
• Europe IFP: scales to $400M by FY28 (vs base $250M)
• AI cost-structure: holds at 30% efficiency edge

Financial outputs:

• FY28 Revenue: $2,400M (vs base $2,100M)
• FY28 Adj EBITDA: $300M (14% margin)
• FY30 Revenue: $3,500M
• FY30 Adj EBITDA: $600M (17% margin)

Valuation (DCF + multiples):

• DCF (15% discount, 6% terminal): $98
• Multiples (EV/IFP 3.5x × FY30 $4,000M = $14B): $115
• Triangulated bull: $100/share

Triggers: Multiple consecutive quarters of <60% GLR + Lemonade Car >$300M IFP + EU acceleration

Base Case ($72/share, 45% probability)

Per Step 14 — sustained execution per management commitments. Q4 2026 EBITDA-positive locked, FY27 first full-year EBITDA-positive, terminal margin 14%.

Bear Case ($40/share, 25% probability)

Operating assumptions:

• IFP CAGR FY25→FY30: +12% (cycle softening + competitive intensity)
• Loss ratio FY28-30: 70-72% (cyclical reversal + AI commoditization)
• Lemonade Autonomous Car: small contribution; not the moat extension expected
• Europe: continues but doesn't accelerate further
• AI cost-structure: compresses to 10-15% efficiency edge by FY28

Financial outputs:

• FY28 Revenue: $1,800M
• FY28 Adj EBITDA: -$100M (still unprofitable)
• FY30 Revenue: $2,200M
• FY30 Adj EBITDA: $50M (2% margin)

Valuation:

• DCF (15% discount, 4% terminal): $35
• Multiples (EV/IFP 2.0x × FY30 $2,800M = $5.6B): $50
• P/B compression (5-6x × FY30 BVPS $9-10): $45-60
• Triangulated bear: $40/share

Triggers: Q1-Q2 2026 GLR back to 70%+, Tesla Insurance scale-up, incumbent AI catches up, CAT event

Severe Case ($20/share, 5% probability)

Conditions (any one of these, or combination):

• Major CAT event: $150M+ EBITDA hit (CA fire severe + FL hurricane major)
• Reinsurance counterparty crisis (Hannover/MAPFRE downgrade to A- or lower)
• GC Synthetic Agents walks away or covenants triggered
• Securities-fraud class action filed (note: none currently exists per Step 4 sweep)

Financial outputs:

• FY28 Revenue: $1,400M (decline from FY26 due to non-renewal of cat-exposed book)
• FY28 Adj EBITDA: -$300M
• New equity issuance required ~$200-300M
• Dilution to ~95M shares
• Stock multiple compresses to 3x P/B

Valuation: $20-25/share

Triggers: Multi-billion dollar cat event + reinsurance counterparty action + cycle severe softening

Probability-Weighted Fair Value Calculation

Result: PWFV $68.4 vs spot $65.71 = +4.1% upside (after rounding).

Stress Tests on Key Variables

Stress Test 1: Loss Ratio Sensitivity

Implication: A 5pp shift in terminal LR moves fair value $15-25/share. Single most important variable.

Stress Test 2: Growth Deceleration

Implication: Each 5pp deceleration shaves $14-16 off fair value.

Stress Test 3: Reinsurance Cession Reversal (forced re-tightening)

If counterparty downgrade forces cession back from 20% → 35%:

• NEP grows 15% slower in FY26-27
• Revenue $1,650M → $1,500M (FY27)
• EBITDA -$80M (FY27 vs base +$50M)
• Fair value: -$10/share (~$62)

Stress Test 4: CAT-Heavy Year

If 3 CAT events in same year ($75M+ EBITDA hit):

• FY26 EBITDA -$120M (vs base -$50M)
• Cash burn extends 2 quarters
• Fair value: -$8/share (~$64)

Base Rate Analysis (Historical Comparisons)

LMND-specific base rates (12-quarter history)

Verdict: Forecast assumptions are within 1-2σ of historical trajectory; not historically unrealistic.

Peer base rates (cohort comparison)

Verdict: LMND base case ROIC 12-18% is realistic but at the high end of peer range. Bull case 18-22% is achievable but ambitious.

Cohort survival base rate (insurtech 2020-2021)

5 years post-IPO outcomes for the cohort:

• Bright Health: failed
• Metromile: acquired
• Hippo: survived, just turned profitable
• Root: survived, just turned profitable
• Lemonade: surviving, approaching profit
• Oscar: survived (different vertical)

Survival rate: ~80% (4 of 5 P&C-relevant). Lemonade is in the surviving cohort — not the failure mode.

Kahneman Bias Checklist

Where Cognitive Biases May Distort the Base Case

1. Optimism bias on AI cost durability — base case may overweight AI moat persistence; bear case correctly captures incumbent catch-up
2. Recency bias on Q4 2025 +37M Adj FCF — last quarter is a poor predictor of normalized run-rate; FY25 average +30M is more reliable
3. Founder-buying-confirmation bias — March 2026 buying is a signal but not a thesis-clincher; do not treat as deterministic
4. Path-to-profitability halo — assume FY27 EBITDA+ might slip to FY28; weight bear scenario accordingly

5. Evidence and Sources

See Source Index. Primary: Step 14 DCF, Step 12 bull/bear bullets, Step 11 risk overlay.

6. Assumption Register Updates

7. Tables and Calculations

See § 4 narrative tables.

Probability-Weighted Fair Value

vs Current spot $65.71: +4.1% upside.

Risk/Reward at Different Entry Prices

8. Open Questions and Data Gaps

1. Q1 2026 actuals — single most important data point to settle structural-vs-cyclical debate
2. Reinsurance counterparty action — most underappreciated tail risk
3. Tesla Insurance scale disclosure — competitive intensity for Lemonade Autonomous Car

Next-Step Dependencies

Step 16 (Variant Perception & Catalysts) reads this Step 15 to identify what the market may be missing. Step 18 (Portfolio Fit) uses the scenario weighting for sizing.

Source Index